ZAI LAB LTD
NASDAQ: ZLAB (Zai Lab Limited)
Last update: 3 hours ago19.22
-0.46 (-2.34%)
| Previous Close | 19.68 |
| Open | 19.52 |
| Volume | 466,619 |
| Avg. Volume (3M) | 865,339 |
| Market Cap | 2,170,371,328 |
| Price / Sales | 4.91 |
| Price / Book | 3.45 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2026 |
| Profit Margin | -60.26% |
| Operating Margin (TTM) | -52.88% |
| Diluted EPS (TTM) | -2.50 |
| Quarterly Revenue Growth (YOY) | 22.20% |
| Total Debt/Equity (MRQ) | 23.72% |
| Current Ratio (MRQ) | 3.26 |
| Operating Cash Flow (TTM) | -186.46 M |
| Levered Free Cash Flow (TTM) | -184.48 M |
| Return on Assets (TTM) | -15.50% |
| Return on Equity (TTM) | -32.05% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Zai Lab Limited | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -5.0 |
| Technical Oscillators | 2.0 |
| Average | -1.67 |
|
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Core |
| % Held by Insiders | 1.47% |
| % Held by Institutions | 52.08% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Bamco Inc /Ny/ | 31 Mar 2026 | 1,658,318 |
| Rock Springs Capital Management Lp | 31 Mar 2026 | 814,707 |
| C Worldwide Group Holding A/S | 31 Mar 2026 | 510,000 |
| B Group, Inc. | 31 Mar 2026 | 450,646 |
| Nan Fung Trinity (Hk) Ltd | 31 Mar 2026 | 346,466 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |